Form 4 Filing for NovaBridge Biosciences

This filing details transactions by Xu Cong Claire, SVP of Clinical Development at NovaBridge Biosciences. On July 4, 2026, Claire acquired 12,432 Ordinary Shares (represented by ADSs) with a transaction code "M" and a price of $0.00. Following this, 5,405 Restricted Share Units (RSUs) were disposed of, with each RSU representing a contingent right to one ADS. On July 6, 2026, Claire disposed of 4,485 Ordinary Shares (represented by ADSs) at a price of $0.89 per share. The post-transaction share count for ordinary shares is 298,101.